Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct;88(4):371-5.
doi: 10.1111/cge.12505. Epub 2014 Oct 28.

Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru

J Abugattas  1 , M Llacuachaqui  2 , Y Sullcahuaman Allende  3   4 , A Arias Velásquez  3 , R Velarde  1 , J Cotrina  1 , M Garcés  1 , M León  1 , G Calderón  1 , M de la Cruz  1 , P Mora  1 , R Royer  2 , J Herzog  5 , J N Weitzel  5 , S A Narod  2
Affiliations

Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru

J Abugattas et al. Clin Genet. 2015 Oct.

Abstract

The prevalence of BRCA1 and BRCA2 mutations among breast cancer patients in Peru has not yet been explored. We enrolled 266 women with breast cancer from a National cancer hospital in Lima, Peru, unselected for age or family history. DNA was screened with a panel of 114 recurrent Hispanic BRCA mutations (HISPANEL). Among the 266 cases, 13 deleterious mutations were identified (11 in BRCA1 and 2 in BRCA2), representing 5% of the total. The average age of breast cancer in the mutation-positive cases was 44 years. BRCA1 185delAG represented 7 of 11 mutations in BRCA1. Other mutations detected in BRCA1 included: two 2080delA, one 943ins10, and one 3878delTA. The BRCA2 3036del4 mutation was seen in two patients. Given the relatively low cost of the HISPANEL test, one should consider offering this test to all Peruvian women with breast or ovarian cancer.

Keywords: BRCA1; BRCA2; Peru; breast cancer; hereditary.

PubMed Disclaimer

Conflict of interest statement

The authors declare that no conflict of interest exists.

References

    1. Globocan 2002. International Agency for Research on Cancer. Available from: http://www-dep.iarc.fr/
    1. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nature Reviews Cancer. 2004 Sep;4(9):665–76. - PubMed
    1. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007 Jun 28;447(7148):1087–93. - PMC - PubMed
    1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003 May;72(5):1117–30. - PMC - PubMed
    1. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994 Mar 19;343(8899):692–5. - PubMed

Publication types

LinkOut - more resources